Dendreon Corp fka DNDNQ

[croumagnon]

"From a patient-advocacy standpoint, surely the delay in obtaining 56 more events pales in comparison to the nightmare scenario where: a) Provenge really does have good efficacy; b) the new 9902b trial fails; and c) the old 9902b trial would have succeeded."

I agree with you. The SPA change made sense regarding the interim, to give it a better chance, however shrinking the timeline of the final by a few months to sacrifice some chances for meeting the goal was, at best, a foolish endeavor. I also agree with your previously stated opinion that the whole final change is a bit suspicious and hinting to the fact that DNDN was aiming to keep investor interest during that period of time rather than trying to help the patients...